1. Health

Discuss in my forum

Carol Eustice

Fostamatinib for Rheumatoid Arthritis: Disappointing Phase III Results Released

By April 5, 2013

Follow me on:

If you are a person who likes to follow what's in the pipeline for arthritis, you likely know that AstraZeneca has been developing fostamatinib for rheumatoid arthritis. Fostamatinib is an oral disease-modifying anti-rheumatic drug (DMARD). Fostamatinib has been viewed as the next competitor to injectable biologic drugs, such as Humira, and the newest oral treatment for rheumatoid arthritis, Xeljanz. In the latest trial results (OSKIRA-1), however, fostamatinib only met one of two goals.

In the OSKIRA-1 Phase III study, fostamatinib achieved statistically significant improvement in the signs and symptoms of rheumatoid arthritis at 24 weeks compared to placebo. But, fostamatinib did not show x-ray evidence of improvement in the progression of joint damage. Side effects included hypertension, diarrhea, nausea, headache, and the common cold.

The results were disappointing for those with high hopes for fostamatinib. Researchers will wait for more results to further evaluate the experimental drug. Results from OSKIRA-2 and OSKIRA-3 are due to be released in the second quarter of 2013.

Related Articles:

Follow Me:

Facebook | Twitter | Message Board | Newsletter

Photo by Brad Killer (iStockphoto)

Comments
March 30, 2014 at 5:40 pm
(1) Ngan says:

Have you ever thought about publishing an e-book or guest authoring on other blogs?

I have a blog based upon on the same information you discuss and would really
like to have you share some stories/information. I
know my visitors would value your work. If you are even remotely interested, feel free
to send me an e-mail.

Leave a Comment

Line and paragraph breaks are automatic. Some HTML allowed: <a href="" title="">, <b>, <i>, <strike>

©2014 About.com. All rights reserved.

We comply with the HONcode standard
for trustworthy health
information: verify here.